SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that Taylor Sandison, M.D., M.P.H., has been named chief
medical officer (CMO) of the company. Dr. Sandison has been serving as
acting chief medical officer of Cidara since September 2016. As CMO, he
will continue to lead the global clinical development of CD101 IV,
Cidara’s novel echinocandin antifungal, currently in Phase 2 clinical
trials, as well as the expanding pipeline of anti-infective candidates
generated by the company’s Cloudbreak™ immunotherapy platform.
“Dr. Sandison’s depth and breadth of experience in anti-infective
clinical development has been tremendously valuable to Cidara,” said
Jeffrey Stein, Ph.D., president and chief executive officer of Cidara.
“We are fortunate to have his clinical leadership as we advance our
portfolio of drug candidates to treat serious fungal and bacterial
infections.”
Dr. Sandison has been with Cidara since October 2015, first serving as
the company’s senior medical director. Prior to joining Cidara, he
served as senior medical director at Cubist Pharmaceuticals, Inc. from
July 2014 to January 2015 and then, following Merck’s acquisition of
Cubist, as senior medical director at Merck from February to October
2015. Dr. Sandison also has held positions at Trius Therapeutics and
Novartis Diagnostics, and served as a faculty member in the Department
of Medicine at both Stanford University and the University of Washington.
Dr. Sandison received B.S. and B.A. degrees from Dartmouth College, and
M.D. and M.P.H. degrees from the University of Washington. He completed
residency training at the University of Colorado and fellowship training
at the University of Washington, and holds board certifications in both
infectious diseases and internal medicine.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, CD101 IV, through Phase 2
clinical trials and is developing CD201, a bispecific immunotherapy, for
the treatment of multi-drug resistant Gram-negative bacterial
infections. CD101 IV has improved pharmacokinetics and expanded utility
across patient settings compared to existing echinocandins. CD101 IV is
the only once-weekly therapy intended for the treatment and prevention
of life-threatening invasive fungal infections. CD201 is the first drug
candidate selected from Cidara’s novel Cloudbreak™ immunotherapy
platform and is designed to specifically direct a patient’s immune cells
to attack and kill bacterial pathogens. Cidara recently received a grant
for up to $6.9 million from CARB-X (Combating Antibiotic Resistant
Bacteria Accelerator) to advance the development of CD201. Cidara is
headquartered in San Diego, California. For more information, please
visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the effectiveness, safety, and other attributes
of CD101 and CD201 and other potential product candidates, including the
potential for these compounds to successfully treat fungal or bacterial
infections, including those caused by resistant pathogens, and
potentially transform the way infectious diseases are treated, and the
potential for the Cloudbreak platform to result in future drug
candidates. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success and timing of Cidara’s
preclinical studies and clinical trials; regulatory developments in the
United States and foreign countries; changes in Cidara’s plans to
develop and commercialize its product candidates; Cidara’s ability to
obtain additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-K most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were
made.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170425005275/en/
Cidara Therapeutics, Inc.
INVESTOR CONTACT:
Westwicke
Partners, LLC
Robert H. Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com
